Nifty Pharma's PB is more expensive than 85% of the last 5 years.
The Nifty Pharma PE ratio is 45.64 as of 19 November 2026, about 36% above its 5-year median of 33.62, which places it in significantly overvalued territory on a historical basis.
| Period | Median PE | Current vs Median |
|---|---|---|
| Full history | 34.59 | +31.95% |
| 15 Years | 37.31 | +22.33% |
| 10 Years | 35.12 | +29.95% |
| 7 Years | 33.41 | +36.59% |
| 5 Years | 33.62 | +35.75% |
| 3 Years | 34.96 | +30.55% |
| 1 Year | 36.98 | +23.42% |
Series start. P/E is published from 1 Jul 2005. Index values go back to 1 Jan 2001.
Index earnings are the profits behind the index level: the closing value divided by the P/E ratio, in index points. The line moves in steps because it changes only when trailing four-quarter profits are updated or the constituents change. Compare it with price to see whether a move came from earnings or from a change in what investors pay for them.
Nifty Pharma earnings grew +7.78% a year over the last 5 years, while the index moved +16.04% a year and its P/E went from 31.5 to 45.6.
Earnings growth is annualised from the last trading day at or before the start of each window to 19 Nov 2026. Price growth uses the index level over the same two dates, excluding dividends. EPS is undefined on days with no published P/E, so those days are skipped. Past growth, not a forecast.
2 ETFs and 2 index funds track this index. Prices and NAVs as of 18 Nov 2026.
| ETF | Symbol | Price | NAV | Premium | 1Y |
|---|---|---|---|---|---|
| Nippon India Nifty Pharma ETF | PHARMABEES | 29.23 | - | - | +25.19% |
| ICICI Prudential Nifty Pharma ETF | PHARMAIETF | 28.2 | - | - | - |
| Fund | AMC | NAV | Since |
|---|---|---|---|
| ICICI Prudential Nifty Pharma Index Fund | ICICI Prudential Asset Management Company Limited | 21.8318 Nov 2026 | 2022 |
| Kotak Nifty Pharma Index Fund | Kotak Mahindra Asset Management Company Limited. | - | 2026 |
Listed for information only, not a recommendation. Check expense ratio and tracking difference before investing.
1-year holding windows since 2005 returned a median of +12.97% (best +95.15%, worst -33.08%).
Today's PE of 45.79 sits in band 5 of 5 of this index's history (PE above 44.3). From this band, 5-year forward returns had a median of +6.79% a year and were positive in 82% of windows (1,053 windows since 2005).
View full performance and risk
Returns as of October 2026, from the NSE factsheet for the Nifty Pharma. 1-year returns are absolute; 5-year returns are annualized.
The Nifty Pharma contains 20 constituents.
23 July 2026: Added Sai Life Sciences Ltd.. Removed J.B. Chemicals & Pharmaceuticals Ltd..
Constituent list as of 15 November 2026, sourced from NSE Indices. Weights as of 30 October 2026, from the NSE factsheet.
Summarised from NSE's official methodology document (PDF) for the Nifty Pharma; the PDF is authoritative.
Get weekly market insights and valuation updates delivered to your inbox.
As of 19 November 2026, the Nifty Pharma PE ratio is 45.64. That is about 36% above its 5-year median of 33.62 and about 23% above its 1-year median of 36.98.
On a historical basis it screens as significantly overvalued. Its current PE of 45.64 sits above every median window: 1-year (36.98), 3-year (34.96), 5-year (33.62), 7-year (33.41), 10-year (35.12), 15-year (37.31) and full-history (34.59).
Over the past five years its median PE has been 33.62, and over the past three years 34.96. Today's 45.64 is toward the upper end of that historical range.
The Nifty Pharma contains 20 stocks. By number of companies, its largest sectors are Healthcare (20 stocks).
As of October 2026, the Nifty Pharma total return (with dividends reinvested) is +23.05% over the past year and +15.17% annualized over the past five years. One-year figures are absolute; multi-year figures are annualized (CAGR). Data from the NSE factsheet.
Over the year to October 2026, the Nifty Pharma had an annualized volatility (standard deviation of daily returns) of 14.21%. Its beta versus the Nifty 50 is 0.53, meaning it has moved less than the broad market.
Across every one-year holding window since 2005, the Nifty Pharma total return has a median of +12.97%, with the best window at +95.15% and the worst at -33.08%. Based on NSE Total Returns Index data; a past distribution, not a prediction.
The Nifty Pharma currently trades at a PE of 45.79, in band 5 of 5 of its own PE history. Across 1,053 overlapping 5-year windows since 2005 that began in this band, the median forward return was +6.79% a year, positive in 82% of windows. A past distribution, not a prediction.
Nifty Pharma earnings, measured as the index level divided by its P/E, grew +7.78% a year over the last 5 years, while the index itself moved +16.04% a year and its P/E rose from 31.54 to 45.64. Past growth, not a forecast.
The Nifty Pharma is rebalanced semi-annually. The review of sectoral indices is undertaken semi-annually based on data for six months ending January and July. Details are in the official NSE methodology document.
Last updated: 19 November 2026.